The value of integrated reporting

Size: px
Start display at page:

Download "The value of integrated reporting"

Transcription

1 The value of integrated reporting Jesper Lindhardt Director Triple Bottom Line Strategy & Performance Management

2 Novo Nordisk at a glance Key facts A focused pharmaceutical company with leading positions in diabetes, haemophilia and human growth hormones Headquartered in Denmark, approx. 40,000 employees in 75 countries, with products marketed in more than 180 countries Double digit top line growth driven by diabetes pandemic Significant growth opportunities fuelled by global presence and strong R&D pipeline Values-based management, guided by the Novo Nordisk Way and the Triple Bottom Line business principle Global leader in diabetes care Global insulin market share: 47% North America: Market share 39% International Operations: Market share 56% Global/regional headquarter Europe: Market share 49% Manufacturing Japan & Korea: Market share 49% China: Market share 58% R&D facility Source: IMS MAT Feb 2014 volume figures

3 Take-home messages on integrated reporting 1. It is really about better management 2. Tells the full story of how value is created 3. Wins trust and build reputation with stakeholders

4 The Triple Bottom Line - our way of doing business

5 Integrated management of business processes Stakeholders - Systematic trend spotting - Reputation tracking - Media tracking Performance - Balanced Scorecard - Personal performance goals - Long-term incentive programme - Annual reporting Integrated thinking in key business processes Governance - Articles of Association - Policies and strategies - Boards and Committees - Annual sustainability review by Board of Directors Aspirations & goals - Strategic long-term targets and 2020 aspirations - Specific short-term targets

6 From stand-alone sustainability to integrated reporting Sustainability Report Environmental Report Annual Financial Report Environmental and Social Report Social Report Environmental and Bioethics Report Integrated Annual reporting

7 A clear purpose Ensure that Novo Nordisk lives up to all applicable legal and reporting obligations and standards as a listed company Explain the investment case to existing and potential investors PositionNovo Nordisk as a leader within diabetes, protein-based therapies and sustainability to a broad range of Novo Nordisk s stakeholders

8 Long-term targets on all dimensions of the Triple Bottom Line Long-term targets from Annual Report 2012

9 The efforts to reduce C0 2 emissions have generated direct financial benefits Example of innovative partnership as part of climate strategy Impact Accumulated impact from all climate strategy initiatives : 150,000 tons of CO 2 reduced from energy savings projects DKK 154 million total investment From 2010, Danish production sites, including the energy-intensive insulin production have been powered by green electricity 2.1 years average payback time DKK 201 million net savings

10 Indonesia has major barriers to diabetes care 7.6 million people live with diabetes in Indonesia 118,000 people with diabetes per endocrinologist <1% achieve treatment targets 6 out of 10 are unaware that they have diabetes illustrative possible complications

11 Education benefits patients and business Education of healthcare professionals Value to society Value to us in collaboration with Steno Diabetes Center and the Indonesian Society of Endocrinology 3,600 Healthcare professionals trained 26,700 patients educated 14% annual growth of people with diabetes treated with insulin 60% of people on insulin reached with our products Patient recognition for dedication to change diabetes and innovative products

12

13 Trust, transparency and performance Some may wonder why business transparency matters. Transparency leads to better performance and accountability. Companies that are transparent perform better over time, and ultimately are more successful. Michel Barnier European Commissioner for Internal Market and Services October 2013

14 Take-home messages on integrated reporting 1. It is really about better management 2. Tells the full story of how value is created 3. Wins trust and build reputation with stakeholders

15 Questions?

16 Complimentary communication UN Global Compact TBL Quarterly Blueprint for Change Programme Environmental Profit & loss account

11. December 2017 Marianne Birkeland Kjær

11. December 2017 Marianne Birkeland Kjær 1 11. December 2017 Marianne Birkeland Kjær Presentation title Date 2 Agenda My Background Novo Nordisk Overview PhD and PostDoc opportunities How to apply for regular positions Novo Nordisk standard recruitment

More information

Slide 1. Investor presentation. Copenhagen 1 November 2018

Slide 1. Investor presentation. Copenhagen 1 November 2018 Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights

More information

The Blueprint for Change Programme - Where economics and health meet: Changing diabetes in Indonesia. Training Showcase: Novo Nordisk.

The Blueprint for Change Programme - Where economics and health meet: Changing diabetes in Indonesia. Training Showcase: Novo Nordisk. Training Showcase: The Blueprint for Change Programme - Where economics and health meet: Changing diabetes in Indonesia Novo Nordisk Authors: Yulia Ivanova, Novo Nordisk Sheena Laursen and Caroline Thon,

More information

Slide 1. Investor presentation. Meet the Management London, 9 August 2018

Slide 1. Investor presentation. Meet the Management London, 9 August 2018 Slide 1 Investor presentation Meet the Management London, 9 August 2018 Manato diagnosed with type 1 diabetes Shirley Ohara, Adelia Stewart has type 2 diabetes Kanagawa, Japan New Orleans, Louisiana, US

More information

The corporate responsibility for health in society

The corporate responsibility for health in society The corporate responsibility for health in society 20 May 2010 The corporate responsibility for health in society Lars Rebien Sørensen CEO & President Novo Nordisk A/S The corporate responsibility for

More information

The Blueprint for Change Programme - Where economics and health meet: Changing diabetes in Indonesia

The Blueprint for Change Programme - Where economics and health meet: Changing diabetes in Indonesia Training Showcase: The Blueprint for Change Programme - Where economics and health meet: Changing diabetes in Indonesia Ivanova, Yulia Novo Nordisk Laursen, Sheena and Thon, Caroline Experimentarium All

More information

novo nordisk R&D AT A GLANCE

novo nordisk R&D AT A GLANCE novo nordisk R&D AT A GLANCE LIU WEI & THOMAS JUNKER ALSTED Liu is a special technician and Thomas is an international postdoc in Research & Development in Novo Nordisk, Denmark PASSIONATE ABOUT PROTEINS

More information

Training showcase: The Blueprint for Change Programme Where economics and health meet: Changing diabetes in Indonesia.

Training showcase: The Blueprint for Change Programme Where economics and health meet: Changing diabetes in Indonesia. Training showcase: The Blueprint for Change Programme Where economics and health meet: Changing diabetes in Indonesia Ivanova, Yulia Novo Nordisk Laursen, Sheena, and Thon, Caroline University College

More information

Green week, CBS, 23 Sep Susanne Stormer Vice President Corporate Sustainability

Green week, CBS, 23 Sep Susanne Stormer Vice President Corporate Sustainability Green week, CBS, 23 Sep. 2013 Susanne Stormer Vice President Corporate Sustainability 2 Let s get things straight: Definition of CSR and corporate sustainability Respect for applicable legislation, and

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission

More information

Industrial careers. Palle Høy Jakobsen Director Head, R&D Academic Fellowships Novo Nordisk A/S

Industrial careers. Palle Høy Jakobsen Director Head, R&D Academic Fellowships Novo Nordisk A/S Industrial careers Palle Høy Jakobsen Director Head, R&D Academic Fellowships Novo Nordisk A/S A Mission Impossible? 10 Jan 2013 2 Career oppertunities. PRIVATE The pharmaceutical industry PUBLIC Universities

More information

Our future workforce. Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk

Our future workforce. Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk Our future workforce Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk ISPE Nordic 17. Nov. 2016 2 Who am I? Head of Quality in Novo Nordisk 48 years Danish Married 5 Children [7-19]

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1 Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Slide 1. Jefferies 2014 Global Healthcare Conference 5-June Karsten Munk Knudsen CVP of Finance & IT at NNI

Slide 1. Jefferies 2014 Global Healthcare Conference 5-June Karsten Munk Knudsen CVP of Finance & IT at NNI Slide 1 Jefferies 2014 Global Healthcare Conference 5-June-2014 Karsten Munk Knudsen CVP of Finance & IT at NNI Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide

More information

Nordea investor meeting. June 18 th, 2018 Kristian Villumsen, EVP Chronic Care

Nordea investor meeting. June 18 th, 2018 Kristian Villumsen, EVP Chronic Care Nordea investor meeting June 18 th, 2018 Kristian Villumsen, EVP Chronic Care Chronic Care represents more than 75% of Coloplast sales and we continue to outgrow the market FY 15/16 Chronic Care Rest of

More information

Establishing LCA in the Healthcare Sector

Establishing LCA in the Healthcare Sector Establishing LCA in the Healthcare Sector Nanja Hedal Kløverpris Abstract Novo Nordisk has used Life Cycle Assessment (LCA) for many years and a few years ago the company took a major step forward and

More information

Coloplast A/S. Investor Presentation Investormøde 16. Januar 2006

Coloplast A/S. Investor Presentation Investormøde 16. Januar 2006 Coloplast A/S Investor Presentation Investormøde 16. Januar 2006 2 Defining Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 5 areas: Ostomy

More information

The Novo Nordisk Foundation Group and Society The Novo Nordisk Foundation Group and Society in brief

The Novo Nordisk Foundation Group and Society The Novo Nordisk Foundation Group and Society in brief The Novo Nordisk Foundation Group and Society in brief Research grants. In 2015, the Novo Nordisk Foundation awarded grants worth a total of DKK 1.159 billion ( 156 million) gross and paid out DKK 914

More information

Business update InvestorDagen

Business update InvestorDagen Slide 1 Business update 28 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities

More information

Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America

Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America Chronic Care represents more than 75% of Coloplast sales and we

More information

Francesc Sistach CEO Specialisterne Spain. Henrik Thomsen Director, COO Specialist People Foundation. The Autism Advantage.

Francesc Sistach CEO Specialisterne Spain. Henrik Thomsen Director, COO Specialist People Foundation. The Autism Advantage. Henrik Thomsen Director, COO Specialist People Foundation Francesc Sistach CEO Specialisterne Spain The Autism Advantage June 29, 2016 THE PROBLEM: People with ASD faces challenges 1 in 68 Communication

More information

What does being there

What does being there Sustainability Report 2003 What does being there mean to you? Shanthala Shamarao and her mother live in India. Shanthala has type 1 diabetes. To me being there means... To me, Novo Nordisk s promise of

More information

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company

More information

Health for Humanity 2020 Goals 2

Health for Humanity 2020 Goals 2 2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus

More information

Financial, social and environmental performance. Our focus is our strength

Financial, social and environmental performance. Our focus is our strength Financial, social and environmental performance Our focus is our strength Performance highlights 2008 2008 2007 Change Financial performance Sales total DKK million 45,553 41,831 9% Diabetes care DKK million

More information

Executive Women s Breakfast Patient Advocacy Real Trust, Real Partnerships for Real Innovation

Executive Women s Breakfast Patient Advocacy Real Trust, Real Partnerships for Real Innovation Executive Women s Breakfast Patient Advocacy Real Trust, Real Partnerships for Real Innovation June 15, 2010, Merck & Co. Inc. This well-attended Executive Women s Breakfast (EWB) featured an executive

More information

Metrology in pharmaceutical production

Metrology in pharmaceutical production Metrology in pharmaceutical production 22/05/2013 1 Metrology in pharmaceutical production Metrologidag 2013 Lorenzo Carli, Ph.D. lzcl@novonordisk.com Contributions from: Jan Lasson Andreasen (R&D) Kirsten

More information

Leicester: A city that doesn t do things by halves

Leicester: A city that doesn t do things by halves Leicester: A city that doesn t do things by halves Cities Changing Diabetes The Cities Changing Diabetes is a programme initiated by Novo Nordisk in response to the fact that over 415 million people worldwide

More information

Leading Intimate Healthcare. Investor presentation Q1 2007/08

Leading Intimate Healthcare. Investor presentation Q1 2007/08 Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1

More information

Leading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products

Leading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio

More information

Creating value through responsible business

Creating value through responsible business Novartis AG Creating value through responsible business Jürgen Brokatzky-Geiger, Global Head Corporate Responsibility Shannon Klinger, Chief Ethics & Compliance Officer and Head Litigation ESG Investor

More information

Chronic illness is a growing market for Novo Nordisk

Chronic illness is a growing market for Novo Nordisk Chronic illness is a growing market for Novo Nordisk Aslam Dalvi - Associate Portfolio Manager Denmark-based global healthcare company Novo Nordisk traces its origins to the first pioneers in insulin production

More information

Jeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine.

Jeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine. Jeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine. 1 2 On April 30 the VU and VUMC transition was completed and we

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing

WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Washington, DC January 14th 16th, 2013 Session 4: Attracting Investments and Generating Revenue Theory, Practice and

More information

YMCA Calgary. Strategic Plan

YMCA Calgary. Strategic Plan YMCA Calgary Strategic Plan YMCA Calgary Strategic Plan 2009 2013 In 2008, YMCA Calgary engaged its staff, Board of Directors and community partners to chart a course for the following five years. The

More information

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset

More information

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011 Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee

More information

A GLOBAL LEADER IN PERSONALIZED NUTRITION

A GLOBAL LEADER IN PERSONALIZED NUTRITION A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking

More information

2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings

2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings CBI Global Transparency Reporting Congress, London 4 April 2017 1 2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings London 4-Apr-2017 CBI Global Transparency Reporting Congress,

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

Slide 1. First six months of London 10 August Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan

Slide 1. First six months of London 10 August Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 1 First six months of 2017 London 10 August 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook

More information

ADVOCATING FOR PATIENTS WITH DIABETES

ADVOCATING FOR PATIENTS WITH DIABETES ADVOCATING FOR PATIENTS WITH DIABETES February 9, 2018 Lashawn Mciver, MD, MPH Senior vice president Government affairs & advocacy Overview 1) Highlight 2017 Advocacy Accomplishments 2) Outline 2018 Advocacy

More information

A world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP

A world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market

More information

Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment

Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Rachael Eckles, JD/MA Director, Regulatory Policy Bristol-Myers Squibb August 10,

More information

Leading Intimate Healthcare

Leading Intimate Healthcare 21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate

More information

Slide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes

Slide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

Slide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes

Slide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information

Statement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July Madam President, Esteemed Delegates, Ladies and Gentlemen.

Statement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July Madam President, Esteemed Delegates, Ladies and Gentlemen. Statement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July 2009 Madam President, Esteemed Delegates, Ladies and Gentlemen. Many thanks for the opportunity to speak here today. I think the

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018 Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic

More information

The challenges of diabetes care in Indonesia. Safeguarding the next generation s health in Malaysia. Paying it forward to improve access in Vietnam

The challenges of diabetes care in Indonesia. Safeguarding the next generation s health in Malaysia. Paying it forward to improve access in Vietnam TBL Quarterly Q1 2013 Investing ahead of the curve Today s actions for tomorrow s health The challenges of diabetes care in Indonesia Safeguarding the next generation s health in Malaysia Paying it forward

More information

Innovative Use of Climate financing Instruments

Innovative Use of Climate financing Instruments Innovative Use of Climate financing Instruments Current DBSA Involvement in Climate Finance Activities The Green Fund is managed by the Development of Bank of South Africa (DBSA) on behalf of Department

More information

EU5 Bariatric Surgery Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020 EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020 Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3

More information

TELECONFERENCE Q November 2015

TELECONFERENCE Q November 2015 TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

Expanding the boundaries of nutrition Luis Cantarell

Expanding the boundaries of nutrition Luis Cantarell Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

ICA Corporate Partnership Program. ICA Corporate

ICA Corporate Partnership Program. ICA Corporate ICA Corporate The Interstitial Cystitis Association is the only non-profit, charitable organization dedicated to improving the quality of healthcare and lives of people with interstitial cystitis (IC).

More information

The acquisition of Fortitech

The acquisition of Fortitech The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale

More information

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY

More information

Mexico Ostomy Drainage Bags Market Outlook to 2020

Mexico Ostomy Drainage Bags Market Outlook to 2020 Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...

More information

Quest for Quality: Immunizations

Quest for Quality: Immunizations Quest for Quality: Immunizations DANE COUNTY IMMUNIZATION COALITION MEMBERSHIP MEETING November 13, 2012 Elaine Rosenblatt MSN, FNP-BC Director, Quality and Care Management UW Medical Foundation/ Unity

More information

KAISER PERMANENTE OF GEORGIA COMMUNITY BENEFIT REPORT

KAISER PERMANENTE OF GEORGIA COMMUNITY BENEFIT REPORT 2016 KAISER PERMANENTE OF GEORGIA COMMUNITY BENEFIT REPORT Partnering to Build Healthy Communities At Kaiser Permanente Georgia, our commitment to improving health has been going strong for more than 30

More information

Towards a Sustainable Global Infrastructure for Medical Countermeasures

Towards a Sustainable Global Infrastructure for Medical Countermeasures Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from

More information

Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Solvay expands its specialty polymers offerings with Ryton PPS acquisition Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty

More information

HUMAN BIOSAMPLES IN PHARMACEUTICAL RESEARCH. A responsible approach

HUMAN BIOSAMPLES IN PHARMACEUTICAL RESEARCH. A responsible approach HUMAN BIOSAMPLES IN PHARMACEUTICAL RESEARCH A responsible approach CONTENTS P 03 P 04 P 08 P 10 P12 P 16 P 17 P 18 P20 OUR APPROACH TO WORKING WITH HUMAN BIOSAMPLES AN INTRODUCTION TO HUMAN BIOSAMPLES

More information

Financial report for the period 1 January 2017 to 30 September November Novo Nordisk A/S Investor Relations

Financial report for the period 1 January 2017 to 30 September November Novo Nordisk A/S Investor Relations report for the period 1 January 2017 to 30 September 2017 1 November 2017 Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 Reported sales increased by 2% to DKK 83.7

More information

Health Plans in Minnesota Partner on Chlamydia Screening. American Sexual Health Association June 21, 2016

Health Plans in Minnesota Partner on Chlamydia Screening. American Sexual Health Association June 21, 2016 Health Plans in Minnesota Partner on Chlamydia Screening American Sexual Health Association June 21, 2016 HealthPartners at a Glance Integrated Care System 22,500 employees Non-Profit, Consumer Governed

More information

STRATEGIC PLAN

STRATEGIC PLAN 2019-2022 STRATEGIC PLAN Thank you for your interest in our work! On behalf of The Friends staff and board of directors, we are excited to share our 2019-2022 Strategic Plan with you. This document represents

More information

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:

More information

THE CHANGING PARADIGM EHS Information Driven Performance

THE CHANGING PARADIGM EHS Information Driven Performance THE CHANGING PARADIGM EHS Information Driven Performance There is an emerging groundswell of change in the Environmental, Health and Safety (EHS) landscape. Companies are expected not only to improve their

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner

Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner report for the period 1 January 2017 to 30 June 2017 9 August 2017 Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

NOVO NORDISK FOUNDATION GROUP FACTS AND RESULTS 2013

NOVO NORDISK FOUNDATION GROUP FACTS AND RESULTS 2013 NOVO NORDISK FOUNDATION GROUP FACTS AND RESULTS 2013 CONTENTS 1 Grants from the Novo Nordisk Foundation 2 Results of the Novo Nordisk Foundation Group 3 The Novo Nordisk Foundation Group and society NOVO

More information

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business

More information

A Blueprint for Breast Cancer Deadline 2020

A Blueprint for Breast Cancer Deadline 2020 A Blueprint for Breast Cancer Deadline 2020 In 1991, the National Breast Cancer Coalition was formed with one mission: an end to breast cancer. NBCC has accomplished much over its twenty plus years: bringing

More information

Adding Value to the NHS, Health and Care, through Research Management, Support & Leadership

Adding Value to the NHS, Health and Care, through Research Management, Support & Leadership Invitation to Comment This new draft strategy has been developed to ensure that the Forum continues to thrive, that we meet the needs of the community over the next five years, and that by acting together

More information

Vision. Mission. Hopelink s Values. Introduction. A community free of poverty

Vision. Mission. Hopelink s Values. Introduction. A community free of poverty Vision A community free of poverty Mission Hopelink s mission is to promote self-sufficiency for all members of our community; we help people make lasting change. Hopelink s Values Growth and Human Potential

More information

Novo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir

Novo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir report for the period 1 January 2013 to 30 June 2013 8 August 2013 Novo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir

More information

NEWSLETTER June Summer greetings from Follicum

NEWSLETTER June Summer greetings from Follicum NEWSLETTER June 2018 Follicum hopes that this newsletter reaches as many of the company's owners and stakeholders as possible. If you wish to follow our continued development, please register your e-mail

More information

Asia-Pacific Electrophysiology Market Outlook to 2020

Asia-Pacific Electrophysiology Market Outlook to 2020 Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...

More information

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets EPIDEMIOLOGY Accurate, in-depth information for understanding and assessing targeted markets WHY ACCURATE MARKET FORECASTS Start with accurate understanding Epidemiology is the study of disease patterns

More information

biomérieux - First-Half 2009 Business Review

biomérieux - First-Half 2009 Business Review PRESS RELEASE biomérieux - First-Half 2009 Business Review First-Half 2009 Sales Up 6% at constant exchange rates and scope of consolidation Up 10.3% at constant exchange rates, including business development

More information

Statistics and Sustainable Development Goals. Christian Bach, September 2015

Statistics and Sustainable Development Goals. Christian Bach, September 2015 Statistics and Sustainable Development Goals Christian Bach, September 2015 UNECE and statistics Regional Commission of the UN 56 Member countries Europe, North America, Central Asia Many other countries

More information

Contribute to our vision of saving lives and ensuring no woman with ovarian cancer walks alone

Contribute to our vision of saving lives and ensuring no woman with ovarian cancer walks alone COMMUNICATIONS AND AWARENESS MANAGER OVARIAN CANCER AUSTRALIA Contribute to our vision of saving lives and ensuring no woman with ovarian cancer walks alone National role Location: Melbourne CBD Position

More information

Publishing as Prentice Hall

Publishing as Prentice Hall 5-1 Discuss what it means to be socially responsible and what factors influence that decision Explain green management and how organizations can go green Discuss the factors that lead to ethical and unethical

More information

August Global Outlook on Serving and Selling Alcohol Beverages Responsibly

August Global Outlook on Serving and Selling Alcohol Beverages Responsibly August 2014 Outlook on Serving and Selling Alcohol Beverages Responsibly Objectives Anheuser-Busch InBev (AB InBev) has commissioned this international survey on the impact of bartenders, waiters and store

More information

What needs to happen in England

What needs to happen in England What needs to happen in England We ve heard from over 9,000 people across the UK about what it is like to live with diabetes and their hopes and fears for the future. Over 6,000 of them live in England;

More information

Engagement Strategy

Engagement Strategy Engagement Strategy 2016-2019 we need to engage with communities and citizens in new ways, involving them directly in decisions about the future of health and care services [NHS England Five Year Forward

More information

Toward a healthier 2020

Toward a healthier 2020 Toward a healthier 2020 How citizenship and sustainability can help more people live healthier lives Photo Credit: Peace Corps We re creating a new vision of health. A vision that expands the ways we ve

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information